| 1. |
- Eskafi, Mahmoud, et al.
(författare)
-
Treatment of sleep apnea in congestive heart failure with a dental device
- 2006
-
Ingår i: Sleep and Breathing. - : Springer Science and Business Media LLC. - 1520-9512 .- 1522-1709. ; 10:2, s. 90-97
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of the present study was to investigate the effect of a mandibular advancement device (MAD) for the treatment of sleep apnea (SA) on plasma brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), and health-related qualify of life (HRQL) in patients with mild to moderate stable congestive heart failure (CHF). Seventeen male patients aged 68.4±5.5 with an apnea–hypopnea index (AHI) ≥10 were equipped with an individually fitted MAD. SA was evaluated using a portable respiratory multirecording system before and after the initiation of treatment. Eleven patients completed follow-up and were evaluated after 6 months of treatment. The AHI reduced from 25.4±10.3 to 16.5±10.0 (p=0.033) compared to baseline and mean plasma BNP levels decreased from 195.8±180.5 pg/ml to 148.1±139.9pg/ml (p=0.035). SA-related symptoms, e.g., excessive daytime sleepiness, were also reduced (p=0.003). LVEF and HRQL were unchanged. We conclude that SA treatment with a MAD on patients with mild to moderate stable CHF appears to result in the reduction of plasma BNP levels. Further studies to investigate if the observed reduction in BNP concentrations also result in improved prognosis are warranted.
|
|
| 2. |
- Eskafi, Mahmoud, et al.
(författare)
-
Treatment of sleep apnea in congestive heart failure with a dental device - The effect on brain natriuretic peptide and quality of life
- 2006
-
Ingår i: Sleep and Breathing. - : Springer Science and Business Media LLC. - 1522-1709 .- 1520-9512. ; 10:2, s. 90-97
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of the present study was to investigate the effect of a mandibular advancement device (MAD) for the treatment of sleep apnea (SA) on plasma brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), and health-related qualify of life (HRQL) in patients with mild to moderate stable congestive heart failure (CHF). Seventeen male patients aged 68.4 +/- 5.5 with an apnea-hypopnea index (AHI) = 10 were equipped with an individually fitted MAD. SA was evaluated using a portable respiratory multirecording system before and after the initiation of treatment. Eleven patients completed follow-up and were evaluated after 6 months of treatment. The AHI reduced from 25.4 +/- 10.3 to 16.5 +/- 10.0 (p = 0.033) compared to baseline and mean plasma BNP levels decreased from 195.8 +/- 180.5 pg/ml to 148.1 +/- 139.9 pg/ml (p = 0.035). SA-related symptoms, e. g., excessive daytime sleepiness, were also reduced (p = 0.003). LVEF and HRQL were unchanged. We conclude that SA treatment with a MAD on patients with mild to moderate stable CHF appears to result in the reduction of plasma BNP levels. Further studies to investigate if the observed reduction in BNP concentrations also result in improved prognosis are warranted.
|
|
| 3. |
- Tannheimer, Markus, et al.
(författare)
-
Auto-PEEP in the therapy of AMS in one person at 4,330 m.
- 2009
-
Ingår i: Sleep and Breathing. - : Springer Science and Business Media LLC. - 1520-9512 .- 1522-1709. ; 13:2, s. 195-199
-
Tidskriftsartikel (refereegranskat)abstract
- Background The human organism is exposed to considerable hypoxic stress at high altitudes. Our intention was to investigate if a special breathing pattern with expiration against the resistance of pursed lips leads to an elevation in oxygen saturation (SaO2). For the first time ever, oxygen saturation was measured continuosly during the initial situation, during self-performed positive end-expiratory pressure breathing (auto-PEEP) itself, and during observation afterwards. Materials and methods The investigation was performed on a 33-year-old male suffering from high-altitude illness (Lake Louise Score, 9) after a 4-day rapid ascent from 350 m to 4,330 m during an expedition to Mount McKinley (6,198 m). SaO2 was measured continuously at 4-s intervals. After a rest of 1.5 h in a dorsal recumbent position with a slightly elevated (about 15°) upper body, the patient used a wristwatch to breathe according to a special time pattern (inspiration 2 s, expiration 8 s against the resistance of pursed lips). After 30 min, breathing was then allowed without any restrictions, and the inspiration/expiration ratio was approximately 1:1. Results There was a relatively sharp rise in SaO2 from an average of 62% to 85% within only 5 min after auto-PEEP began. This was followed by a comparable rise to values of 95% at the end of the auto-PEEP period. During normal breathing, SaO2 decreased slowly within half an hour to values of about 70% and remained at this level. The person reported relief in symptoms and no exhaustion. Vertigo—an indication of hypocapnia caused by hyperventilation—was not observed. Discussion The 30% rise in SaO2 and the improved saturation level after auto-PEEP are remarkable. Elevated intra-thoracal pressure may lead to a reopening of collapsed alveoli in addition to an improved gradient of alveolarcapillary pressure. In addition, a pressure-induced displacement of interstitial fluid resulting in a reduced diffusion distance may lead to improved alveolar-capillary diffusion. This would explain the slower rise in SaO2 after 10 min of auto-PEEP and the elevated level of SaO2 compared to the initial level before auto-PEEP. Conclusion As a result of the substantial and lasting improvement in SaO2 in combination with relief in AMS symptoms and its easy use, auto-PEEP (30 min every 2 h) can be a useful therapy option in the event of high-altitude-induced hypoxia and AMS.
|
|
